PREDSULFAIR II
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREDSULFAIR II (PREDSULFAIR II).
Prednisolone is a corticosteroid with glucocorticoid and mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators. Sulfonamide component provides bacteriostatic action via inhibition of dihydropteroate synthase in bacterial folate synthesis.
| Metabolism | Primarily hepatic via CYP3A4; prednisolone is the active metabolite of prednisone. Sulfonamide is metabolized via N-acetylation and glucuronidation. |
| Excretion | Renal: 70-80% (30-50% as unchanged prednisolone, 20-30% as prednisone and inactive metabolites); Biliary/Fecal: 15-20% |
| Half-life | Terminal elimination half-life of prednisolone (active moiety): 2.1-3.5 hours; clinical context: duration of HPA axis suppression exceeds plasma half-life (12-36 hours). |
| Protein binding | Prednisolone: 70-90% bound to corticosteroid-binding globulin (CBG) and albumin; binding is concentration-dependent and saturable. |
| Volume of Distribution | Prednisolone: 0.4-1.0 L/kg; indicates extensive tissue penetration and distribution into total body water. |
| Bioavailability | Oral prednisolone: 70-90%; Oral prednisone: 60-80% (hepatic conversion to prednisolone); Ophthalmic: minimal systemic absorption (<1%) with standard dosing. |
| Onset of Action | Intravenous: 1-2 hours for peak anti-inflammatory effect; Oral: 1-4 hours; Topical: minutes to hours for dermatologic effects; Ophthalmic: 1-2 hours for intraocular inflammation reduction. |
| Duration of Action | Plasma adrenal suppression: 24-36 hours after single dose; anti-inflammatory effect persists for 12-36 hours; duration varies with dose and route. |
1-2 drops into the affected eye(s) every 4-6 hours; not to exceed 6 doses per day.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No specific adjustment recommended; systemic absorption is minimal. |
| Liver impairment | No specific adjustment recommended; systemic absorption is minimal. |
| Pediatric use | Not recommended for use in children under 2 years of age. For children ≥2 years, same as adult dosing. |
| Geriatric use | No specific adjustment required; use with caution due to potential increased intraocular pressure risk. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PREDSULFAIR II (PREDSULFAIR II).
| Breastfeeding | Prednisolone: Excreted in breast milk; M/P ratio ~0.5. Sulfacetamide: Excreted in low amounts; risk of kernicterus in neonates with hyperbilirubinemia or G6PD deficiency. Use with caution; monitor infant for jaundice, drowsiness, and poor feeding. |
| Teratogenic Risk | First trimester: Class C - potential risk based on animal studies with prednisolone; sulfacetamide not assessed. Second/third trimester: Caution - prednisolone may cause adrenal suppression; sulfacetamide crosses placenta, theoretical risk of kernicterus. Overall: Use only if benefit outweighs risk; monitor for fetal growth restriction. |
■ FDA Black Box Warning
None
| Serious Effects |
Systemic fungal infections, known hypersensitivity to corticosteroids or sulfonamides, viral infections, and pregnant or lactating animals unless benefits outweigh risks.
| Precautions | Prolonged use may cause immunosuppression, delayed wound healing, and secondary infections. Sulfonamides may cause hypersensitivity reactions, keratoconjunctivitis sicca, and blood dyscrasias. Use with caution in animals with diabetes, renal impairment, or hepatic disease. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, glucose, and signs of infection. Fetal ultrasound for growth restriction. Neonatal assessment for adrenal suppression (if high-dose systemic prednisolone). |
| Fertility Effects | No known direct adverse effects on fertility. Chronic infections treated may impact fertility; condition itself may affect reproductive outcomes. |